Kornimate/medical-research-clean huggingface dataset:
induction chemotherapy followed by concurrent chemoradiotherapy in patients with la-npc

Conditions: Nasopharyngeal Carcinoma

Summary: nasopharyngeal carcinoma (npc) is a malignant tumor that originates in nasopharyngeal epithelial cells. it is common in southern china and southeast asia, but the incidence rate is low in most parts of the world. according to the world health organization survey, 80% of nasopharyngeal carcinomas occur in china, with high incidence in southern china, as high as 30-50/100,000, such as guangdong, guangxi, hunan, and fujian. in 2015, chinese cancer statistics showed that there were about 60,600 new cases of nasopharyngeal carcinoma in china, and the number of deaths was about 34,100. radiation therapy is the main treatment for nasopharyngeal carcinoma. early stage i and iia achieved a 5-year survival rate (os) of 90% and 84%, respectively . however, the treatment outcomes of most patients with locally advanced nasopharyngeal carcinoma are not ideal.


Eligibility criteria:
inclusion criteria: 1. age, 18-75 years old. 2. patients with newly histologically confirmed npc. 3. who type ⅱ and ⅲ. 4. tumor staged as ⅲ-ⅳa (according to the 8th ajcc edition). 5. no serious organ dysfunction of heart, lung, liver, kidney. 6. no distant metastasis. 7. hematological examinations:wbc≥3.5×109/l, neut#≥1.5×109/l, plt≥90×109/l, hb≥90g/l. 8. normal liver function test：alanine aminotransferase (alt)、aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤1.5×uln，creatinine clearance ≥60 ml/min. 9. patients must be given written informed consent. exclusion criteria: 1. age \>75 years or \<18years. 2. prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 3. history of previous radiotherapy and chemotherapy. 4. known or suspected to be allergic to platinum and nab-paclitaxel. 5. pregnancy or lactation. 6. any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial. 7. peripheral sensory neuropathy\> grade 1. 8. uncontrolled heart clinical symptoms or diseases.
opioid sparing anesthesia in cervical spine surgery

Conditions: Pain, Postoperative; Pain, Acute; Pain, Chronic; Pain, Nociceptive; Ketamine; Lidocaine; Analgesia; Analgesics; Cervical Spine Surgery

Summary: the aim of this double blind randomized study will be to investigate the effect of an opioid-free anesthesia regimen with a mixture of lidocaine and ketamine in the same syringe versus remifentanyl analgesia in cervical spine surgery.

cervical spine surgery is associated with medium pain scores and perioperative disability. ketamine and lidocaine have all proven but varied analgesic effects. high opioid consumption has been associated with multiple side effects. this double blind clinical trial aims to investigate the possible reduction of opioid use during lumbar spine surgery by administering ketamine and lidocaine. sixty patients will be randomly allocated into two groups. the control group will receive a continuous infusion of remifentanil, while the ketamine-lidocaine (kl) group will receive a continuous infusion of ketamine and lidocaine, during the surgery and shortly after. both infusions will be administered blindly. fentanyl and morphine will be administered to each patient so as to maintain hemodynamic stability and pain relief. the study will eventually compare the need for bolus doses of fentanyl during the surgery and morphine shortly after in each group. multiple hemodynamic parameters, analgesic consumption, possible side effects, patient satisfaction and the oswestry low back pain disability questionnaire will be recorded.

Eligibility criteria:
inclusion criteria: * adult patents * american society of anesthesiologists (asa) class i-iii * elective spine surgery exclusion criteria: * body mass index (bmi) \>35 kg/m2 * contraindications to local anesthetic administration * systematic use of analgesic agents preoperatively * chronic pain syndromes preoperatively * neurological or psychiatric disease on treatment * pregnancy * severe hepatic or renal disease * history of cardiovascular diseases/ arrhythmias/ conduction abnormalities * bradycardia(\<55 beats/minute) * drug or alcohol abuse * language or communication barriers lack of informed consent
efficacy of i/v nalbuphine v/s iv lignocain in attanuation of pressor responseduring laryngeoscopy and intubation in middle age patient planned for thyroid surgery

Conditions: Hemodynamic Stability

Summary: comparison of i/v nalbuphine versus i/v xylocain in attanuation of pressor response during intubation and laryngeoscopy in patients undergoing for thyroid surgery,selection of better supressor agent minimises the drug repated side effects like hypertention tachycardia but also helps in heamodynamically stability at induction.


Eligibility criteria:
inclusion criteria: * middle age(18_40) * asa 1 and 2 * non hypertensive * thyroid patients * patient who gives consent exclusion criteria: * hypertensive * asa 3 and 4 * patient refusal
influence of omeprazole on the anti-platelet action of clopidogrel

Conditions: Coronary Heart Disease

Summary: objectives: a prospective investigation of the effect of omeprazole, a proton pump inhibitor, on the anti-platelet action of clopidogrel. the main decision criterion will concern change in vasp protein phosphorylation under treatment. phosphorylation will be measured before and after administration of omeprazole versus placebo in patients undergoing clopidogrel treatment. type of study: single center, double blind, randomized parallel group study versus placebo, comparing two treatment groups: * clopidogrel + omeprazole + standard regime (beta-blockers, atorvastatin, iec, aspirin) * clopidogrel + placebo+ standard regime (beta-blockers, atorvastatin, iec, aspirin) study population: 120 patients from the cardiology department of brest university hospital, brest (france), receiving a standard treatment comprising a loading dose of clopidogrel followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20 mg/day omeprazole and 20 mg/day placebo treatment groups. the efficacy of clopidogrel will be assessed by inter-group comparison on the vasp test. study period: 7 days' treatment per patient. total study period estimated at 6 months. expected findings: the results should confirm the suspected negative effect of omeprazole on clopidogrel's impact on arterial thrombosis risk, secondarily allowing new recommendations to be drawn up for this association.

preventing recurrence of thrombosis following angioplasty relies on dual-therapy associating the anti-platelet agents aspirin and clopidogrel. this regime is kept up for between 1 and 6 months, depending on the type of stent deployed in the angioplasty. the biological effectiveness of the clopidogrel treatment can be assessed by the vasp test, a new platelet test, results on which have been shown to correlate with risk of thrombosis. a study we ran recently strongly suggested that omeprazole was associated with a poor response to clopidogrel. omeprazole is an anti-ulcer agent frequently prescribed to prevent unwanted side-effects of aspirin, making it frequently associated to clopidogrel in the aftermath of angioplasty. study population: 120 patients from the cardiology department of brest university hospital, brest (france), receiving a standard treatment comprising a loading dose of clopidogrel followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20 mg/day omeprazole and 20 mg/day placebo treatment groups. the efficacy of clopidogrel will be assessed by inter-group comparison on the vasp test. study period: 7 days' treatment per patient. total study period estimated at 6 months.

Eligibility criteria:
inclusion criteria: * patient with indication of aspirin and clopidogrel treatment exclusion criteria: * patient\<18 years * liver disease * drug eluting stent * gastrointestinal ulcus * bleeding * pregnancy

Keywords: clopidogrel omeprazole
modeling of the response to hypofractionated stereotactic pulmonary irradiation

Conditions: Oncology

Summary: identify 18-fluorodeoxyglucose (18f-fdg) positron emission tomography-computed tomography (pet-ct) parameters predictive of tumor response and local control

the identification of robust prognostic and predictive markers could allow the individualization of pulmonary stereotactic radiotherapy treatments and the selection of patients at high risk of relapse, who could then benefit from a dose escalation in order to increase the chances of local control . beyond the pulmonary rts (radiotherapy in stereotactic condition), this study will aim to generate one or more models of multi-scale response to hypofractionated irradiation from biomarkers (biological or images) extracted from preclinical or clinical literature data and to allow simulations of various modified fractionation irradiation schemes, potentially leading to new regimens that reduce side effects and increase therapeutic efficacy.

Eligibility criteria:
inclusion criteria: * age\> 18 years * performance index who (world health organization) ≤ 2 * bronchopulmonary carcinoma not in small cells proved histologically or cytologically (epidermoid, adenocarcinoma, or large cell carcinoma). * tumor classified t1 - t2 (tumor=1-2) n0 (node=0) m0 (metastasis=0) and diameter ≤ 5 cm or tumor classified t3 (≤5cm) n0m0 of the chest wall * tumor located more than 2 cm from the trachea and bronchus stem and more than 1.5 cm from the organs at risk * medically inoperable or refusing surgery * indication of stereotactic radiotherapy validated in multidisciplinary consultation meeting * formulation of consent exclusion criteria: * age \<18 years. * history of pulmonary irradiation * pulmonary surgery of the tumor * different histology of non-small cell carcinoma * patient with a t2 or t3\> 5 cm tumor or patients with a t3 tumor invading a structure other than the chest wall * patient with a tumor within 2 cm of the trachea and bronchus stem and within 1.5 cm of the organs at risk in the proximal area of the no fly zone (defined as a volume located 2 cm in all directions of the proximal bronchial tree - pulmonary metastases * declared pregnancy, breast-feeding * refusal to use effective contraception * against indication to the realization of the pet to the 18fdg (18-fluorodeoxyglucose)(uncontrolled diabetes) * refusal or inability to consent to participate in the study. * estimated life expectancy \<2 months in the absence of treatment * other invasive tumors diagnosed in the previous 2 years, with the exception of non-melanocytic cutaneous carcinomas.
safety, tolerability and pharmacokinetics of mk-0873 following patch application in healthy participants and psoriasis participants (mk-0873-020)

Conditions: Plaque Psoriasis

Summary: this study will evaluate the incidence of erythema and other local cutaneous irritation after administration of mk-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. part i and part ii in healthy participants will be initiated prior to part iii in psoriasis participants. the primary hypotheses of the study are: 1) that mk-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of mk-0873 is \<20 nm in healthy participants and participants with psoriasis.


Eligibility criteria:
inclusion criteria: part i, ii and iii: * female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control; * in good general health; * nonsmoker; part iii only: * has diagnosis of plaque-type psoriasis, and has lesions covering at least 3% of total body surface area; exclusion criteria: part i, ii and iii: * has a history of stroke, chronic seizures or major neurological disease; * has a history of cancer; * is a nursing mother; part iii only: * has nonplaque forms of psoriasis; * has current drug-induced psoriasis; * has received phototherapy, systemic medications/treatments, or used topical medication that could affect psoriasis; * has used any systemic immunosuppressants or biologics within the past 4 weeks.
choline nutrition in children with cystic fibrosis (cf)

Conditions: Cystic Fibrosis

Summary: cystic fibrosis (cf) is a complex disease with a wide range of clinical problems. despite enzyme replacement therapy, children with cystic fibrosis (cf) may still have problems absorbing some nutrients. detailed studies of the nutrient status of children with cf and have found low amounts of choline, an essential dietary nutrient, and altered levels of some amino acids in almost all patients. choline is an essential dietary nutrient that is important in many important body functions, which include proving a source of methyl groups, the structure of cell membranes and in acetylcholine. most choline is present in our diets in a fat known as phosphatidylcholine. research studies have shown that children with cystic fibrosis do not absorb fat, including phosphatidylcholine very well. in previous studies, we showed that choline provided as a dietary supplement for 2 weeks improved choline status in children with cystic fibrosis. the purpose of this research is to find out if choline supplements over a longer duration of 6 months will improve and maintain normal choline status in children with cf.

this is a prospective study involving 34 children attending an outpatient clinic for children with cf. after enrollment, subjects will be followed for 9 months with each child serving as their own control in a repeated measures design. chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. to avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months. the objectives are to 1. determine if supplementation with choline for 6 months corrects biochemical markers of choline deficiency and improves indices of reduced methylation capacity (including methionine, sam, sam/sah) and redox status (gsh/gssg) based on measures of blood and urine 2. determine whether or not choline supplementation decreases plasma pro-inflammatory mediators 3. determine if choline supplementation improves the low n-6 and n-3 fatty acids levels in children with cf, 4. explore if choline supplementation has the potential to have clinical relevance in reducing recurrent inflammation, and improve pulmonary function and/or reduce liver disease.

Eligibility criteria:
inclusion criteria: * children with cystic fibrosis of known genotype. exclusion criteria: * no hospitalizations within the previous month * not receiving parenteral nutrition * fev1 \> 50% at enrollment * bmi and weight for age z-scores \> 5th percentile * non smokers * no asthma * not taking any lipid supplement or other agent designed to effect glutathione status.

Keywords: cystic fibrosis choline nutrition choline and methyl metabolism cf and oxidative stress
dose reduction in thoracic ct

Conditions: Lymphoma

Summary: hypothesis: does a 50% reduction in radiation in dose significantly affect the diagnostic quality of chest ct

patients with lymphoma are recruited and have a follow up ct performed at 50% of the standard exposure parameters. the studies are compared for image quality with a recent (\<3 months) thoracic ct performed at standard exposure parameters.

Eligibility criteria:
inclusion criteria: * patients with lymphoma exclusion criteria: * no recent (\<3 months) thoracic ct
lycopene in preventing prostate cancer in healthy participants

Conditions: Prostate Cancer

Summary: rationale: chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. the dietary supplement lycopene may prevent the development of prostate cancer. purpose: this phase i trial is studying the side effects and best dose of lycopene in preventing prostate cancer in healthy participants.

objectives: * determine the toxicity and safety of lycopene supplementation as chemoprevention for prostate cancer in healthy participants. * determine the pharmacokinetics of this agent in these participants. * determine the dose range of this agent in these participants. outline: this is a dose-escalation study. participants ingest a single-dose of oral lycopene over a maximum of 15 minutes on day 1. cohorts of 5 participants receive escalating doses of lycopene until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 5 participants experience dose-limiting toxicity. participants are evaluated periodically for 28 days. projected accrual: a total of 25 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * healthy participants in good medical condition * no chronic medical conditions * no regular use of prescription medications * no evidence of psychiatric disorder * non-smoker * former smokers allowed provided they have not smoked within the past 3 months * no history of alcohol abuse * serum lycopene concentration \< 700 nm patient characteristics: age * 18 to 45 performance status * karnofsky 100% life expectancy * not specified hematopoietic * hemoglobin ≥ 13.0 g/dl * wbc ≥ 4,000/mm\^3 * platelet count 150,000-400,000/mm\^3 hepatic * ast and alt ≤ 75 u/l * bilirubin ≤ 2.0 mg/dl * no liver disease renal * creatinine ≤ 1.5 mg/dl * no renal disease cardiovascular * no cardiovascular disease * no abnormal ekg other * within 15% of ideal body weight * no history of gastrointestinal malabsorption or other condition that would preclude drug absorption * no alcohol consumption within the past 72 hours * no allergy to tomato-based products * no history of cancer * no diabetes mellitus * no other illness that would preclude study participation prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * at least 4 weeks since prior experimental drugs * more than 14 days since prior prescription drugs * no concurrent participation in another experimental trial * no concurrent prescription drugs

Keywords: prostate cancer
the infected bone nonunion and soft tissue defect of long bone treated simultaneously with ilizarov technique

Conditions: Trauma; Orthopedic Surgery Complications

Summary: in this retrospective study, the investigators evaluated the clinical and functional results of infected nonunion of the long bone with soft-tissue defects treated simultaneously with ilizarov technique combining open dressing change in 22 patients. the investigators wanted to find out whether that the internal bone transport with external fixator combining open dressing change is a valuable method to treatment for those patients with infected bone nonunion and poor condition of the soft tissue such as sinus, skin defect.

from january 2002 to now, totally 22 patients (18 males, 4 females) were underwent internal bone transport for infected nonunion in the long bone with soft-tissue defects. the mean age of the patients was 36.5 years (range, 19 to 57). the infected nonunion occurred on the femur in 1 patients, the tibia in 21 patients. the hybrid mono-lateral limb reconstruction external fixator was used, combined with bone transport. the results were evaluated by the classification of the association for the study and application of the method of ilizarov (asami) which divided into bone and functional categories

Eligibility criteria:
inclusion criteria: * patients with infected nonunion of long bone with soft tissue defects or sinus, without systemic illness that could affect their immunologic status (e.g., aids, diabetes mellitus, liver cirrhosis). exclusion criteria: * patient noncooperation and an age of less than 18 years

Keywords: infected ilizarov
an observational time and motion study of trastuzumab subcutaneous (sc) and intravenous (iv) formulations in human epidermal growth factor receptor 2 (her2)-positive early breast cancer (ebc)

Conditions: Breast Cancer

Summary: this prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab (herceptin) sc and iv formulations in her2-positive ebc. this is a sub-study of the clinical study mo22982 (nct01401166/prefher).


Eligibility criteria:
inclusion criteria: * participants from the mo22982 (prefher) clinical trial who consent to the presence of an observer to record data for the study during administration of trastuzumab * members of the care team responsible for management of participants from the mo22982 (prefher) clinical trial who also consent to the presence of an observer during administration of trastuzumab exclusion criteria: * none specified
study of uptake, break down and elimination of an investigational drug in healthy volunteers

Conditions: Alzheimer's Disease

Summary: this study is being performed in order to learn more about a new drug (possible as treatment for people with alzheimer's disease and other conditions with cognitive dysfunction (memory and attention problems)) and how it is handled by the body by giving the drug to healthy volunteers with different genotypes.


Eligibility criteria:
inclusion criteria: * physically healthy volunteers * participation in a previous study for genotyping for identification to be extensive, intermediate or poor metaboliser (cyp2d6 enzyme) exclusion criteria: * history of clinically significant diseases or illness. * ues of any prescribed or non-prescribed medications from 2 weeks prior to first treatment day except for paracetamol and otc adrenergic nasal spray.

Keywords: mass balance azd3480, pharmacokinetics, healthy volunteers